Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922)
6.53
-0.02 (-0.31%)
Last updated: Jan 21, 2026, 10:02 AM HKT
HKG:6922 Revenue
Cryofocus Medtech (Shanghai) had revenue of 51.11M CNY in the half year ending June 30, 2025, with 170.20% growth. This brings the company's revenue in the last twelve months to 85.16M, up 105.16% year-over-year. In the year 2024, Cryofocus Medtech (Shanghai) had annual revenue of 53.53M with 30.72% growth.
Revenue (ttm)
85.16M CNY
Revenue Growth
+105.16%
P/S Ratio
16.81
Revenue / Employee
308.56K CNY
Employees
276
Market Cap
1.57B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.53M | 12.58M | 30.72% |
| Dec 31, 2023 | 40.95M | 13.80M | 50.83% |
| Dec 31, 2022 | 27.15M | 4.72M | 21.06% |
| Dec 31, 2021 | 22.43M | 13.37M | 147.69% |
| Dec 31, 2020 | 9.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |